- Olfson M, Marcus SC, Pincus HA, Zito JM, Thompson JW, Zarin DA. Antidepressant prescribing practices of out-patient psychiatrists. Arch Gen Psychiatry 1998;55: 310-16.
- Zohar J, Westenberg HGM. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors Acta Psychiatr Scand 2000;101(Suppl 403); 39-49.
- Priest RG, Vize C, Roberts A, Roberts M, Tylee A. Lay people's attitudes to treatment of depression: results of opinion poll for Defeat Depression Campaign just before its launch. Br Med J 1996;313:858-9.
- Lejoyeux M, Ades J. Antidepressant discontinuation: a review of the literature. J Clin Psychiatry 1997;58(Suppl 7):11-16.
- Schatzberg AF, Haddad P, Kaplan EM, et al. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition. J Clin Psychiatry 1997;58(Suppl 7):5-10.
- Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44:77-87.
- Dean AJ, Moses GM, Vernon J. Suspected withdrawal syndrome after cessation of St John's Wort. Ann Pharmacother, in press.
- Schatzberg AF, Haddad P, Kaplan EM, et al. Possible biological mechanisms of the serotonin reuptake inhibitor discontinuation syndrome. J Clin Psychiatry 1997; 58(Suppl 7):23-27.
- Dilsaver SC. Withdrawal phenomena associated with anti-depressant and antipsychotic agents. Drug Safety 1994; 10: 103-14.
- Whittal ML, Otto MW, Hong JJ. Cognitive-behavior therapy for discontinuation of SSRI treatment of panic disorder: a case series. Behav Res Ther 2001;39:939-45.
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders: DSM-IV. Washington, DC: American Psychiatric Association 1994.
- Haddad P. Do antidepressants have any potential to causeaddiction? J Psychopharmacol 1999;13:300-7.
- Medawar C. The antidepressant web: marketing depression and making medicines work. Int J Risk Safety Med 1997;10: 75-126.
- Donoghue J, Hylan TR. Antidepressant use in clinical practice: efficacy versus effectiveness. Br J Psychiatry 2001; 179(Suppl 42):S9-17.
- Di Matteo V, De Blasi A, Di Giulio C, Esposito E. Role of 5-HT2C receptors in the control of central dopamine function. TiPS 2001;5:229-32.
- D'Aquila PS, Collu P, Gessa GL, Serra G. The role of dopamine in the mechanism of action of antidepressant drugs. Eur J Pharmacol 2000;405:365-73.
- Lee K, Kornetsky C. Acute and chronic fluoxetine treatment decreases the sensitivity of rats to rewarding brain stimulation. Pharmacol Biochem Behav 1998;60: 539-44.
- Ichikawa J, Kuroki T, Meltzer HY. Differential effects of chronic imipramine and fluoxetine on basal and amphetamine-induced extracellular dopamine levels in rat nucleus accumbens. Eur J Pharmacol 1998;350:159-64.
- Zangen A, Nakash R, Overstreet DH, Yadid G. Association between depressive behaviour and absence of serotonin-dopamine interaction in the nucleus accumbens. Psychopharmacology 2001;155:434-9.
- Tremblay LK, Naranjo CA, Cardenas L, Herrman N, Busto UE. Probing brain reward system function in major depressive disorder. Arch Gen Psychiatry 2002;59:409-16.
- Hyman SE, Nestler EJ. Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 1996;153:151-2.
- Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54: 597-606.
- Mayberg HS, Brannan SK, Tekell JL, et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 2000;48:830-43.
- Sartorius N. The economic and social burden of depression. J Clin Psychiatry 200;162(Suppl 15):8-11.
Drug and Alcohol Review
Volume 21, 2002 - Issue 4